Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 23;9(3):96-100.
doi: 10.1097/XCE.0000000000000197. eCollection 2020 Sep.

Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists

Gerardo Rodriguez-Araujo  1
Affiliations
Review

Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists

Gerardo Rodriguez-Araujo. Cardiovasc Endocrinol Metab. .

Abstract

Type 2 diabetes mellitus is not just a risk factor but a progression factor for a plethora of multi-organ complications, including the liver and the vascular system. The profibrogenic-inflammatory liver disease nonalcoholic steatohepatitis affects patient's mortality and overall cardiovascular and liver-related complications. There is an evident overlap between these diseases; therefore, there are important implications for endocrinologists, cardiologists, and hepatologists when treating these patients. In addition, as newly approved nonalcoholic steatohepatitis pharmacotherapy is expected to be available early this year, clinicians need to be able to identify patients with type 2 diabetes mellitus that are at risk of advanced liver fibrosis to establish adequate and efficient management plans to limit or avoid cardiovascular or liver-related complications. In this review, we summarize the current knowledge in the nonalcoholic steatohepatitis field with potential value for clinicians focusing on the implications of the overlap between type 2 diabetes mellitus, cardiovascular disease, and nonalcoholic steatohepatitis, the available diagnostic tools for risk stratification, management pathways, and nonalcoholic steatohepatitis pharmacotherapy, including antidiabetic and cardiovascular drugs that may be beneficial or detrimental to their patients.

Keywords: cardiology; cardiovascular disease; clinical implications; diabetes; endocrinology; hepatology; liver disease; non alcoholic fatty; non alcoholic steatohepatitis; pharmacotherapy; research and development.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Pathophysiology and pharmacotheraphy of NAFLD.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the united states. Gastroenterology. 2015; 148:547–555 - PubMed
    1. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019; 71:793–801 - PubMed
    1. Alkhouri N, Poordad F, Lawitz E. Management of nonalcoholic fatty liver disease: lessons learned from type 2 diabetes. Hepatol Commun. 2018; 2:778–785 - PMC - PubMed
    1. Petit JM, Vergès B. GLP-1 receptor agonists in NAFLD. Diabetes Metab. 2017; 43Suppl 12S28–2S33 - PubMed
    1. Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, et al. ; PIONEER 2 Investigators. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019; 42:2272–2281 - PubMed
  NODES
Note 2
twitter 2